• by:
  • December 1st, 2021
  • Category: news

Radiomics joins the FNIH Biomarkers Consortium

Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).


Radiomics joins the FNIH Biomarkers Consortium

Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).

Radiomics is proud to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC).

The Consortium brings together members from the biotechnology and pharmaceutical industry, the National Institutes of Health (NIH), the Food and Drug Administration (FDA), not-for-profit foundations, and patient advocacy groups to develop and execute pre-competitive projects aimed at improving healthcare through meaningful measurements, bridging the gap between basic research and practical needs for advancing drug development and regulatory science.

The goals of the Consortium include:

  • facilitating the development and the seeking of regulatory approval for biomarkers using new and existing technologies
  • developing evidence to help qualify biomarkers for specific applications in diagnosing disease, predicting therapeutic response or improving clinical practice
  • generating information useful to inform regulatory decision making
  • making consortium project results broadly available to the entire scientific community

Since its founding in 2006, the BC has launched over 35 projects that have generated tools and knowledge that definitively and visibly move the field forward. These projects have generated over 50 project team publications and have been cited in publications over 800 times. Importantly, these projects have generated 9 tools that are being used by the pharmaceutical industry in drug development to make clinical trial decisions. Finally, the work of BC projects has contributed to 5 FDA guidance documents, 1 FDA biomarker qualification, and the advancement of 14 therapies toward FDA approval.

Radiomics is delighted to contribute with its cutting-edge technology and expertise in quantitative imaging analysis, AI, and data science and will be represented by Radiomics CSO Dr. Sean Walsh, CMO Dr. Mariaelena Occhipinti, and biomarker expert Dr. Nina Flerin.

Organizations such as Radiomics provide the technological expertise to mine hidden data embedded in medical images as potential biomarkers and endpoints for drug development,” said Steve Hoffmann, Associate Vice President of Research Partnerships at FNIH and Director of the Biomarkers Consortium. “Their engagement with the FNIH Biomarkers Consortium will augment the focus and incorporation of AI technologies in projects across multiple therapeutic areas to benefit our shared mission of improving healthcare.

"The FNIH Biomarkers Consortium is a vibrant and dynamic partnership and community committed to improving healthcare by advancing science through collaboration and innovation. This is a natural space for Radiomics to engage and contribute." said Dr. Sean Walsh.



About Radiomics

Founded in 2016 and based in Liège, Radiomics is a Belgian AI powered research organization for next-generation image analysis, based on the unique experience of its founders, pioneers in radiomic science. Oncology being radiomics initial focus area, we have developed promising applications in various other therapeutic areas, such the respiratory field. Radiomics uses its advanced image analysis technology based on AI, deep learning, machine learning, and federated learning to obtain quantitative biomarker measurements from medical imaging, in a repeatable, reliable, and relevant manner. Its goal is to support decision-making through insights and optimize pharmaceutical and biotech companies’ clinical trials and drug development studies and provide clinicians with a patient-centered approach based on personalized medicine.

Media Contact

Fabrizia Candido
Account & PR Manager
[email protected]


About the Biomarkers Consortium:

The Foundation for the National Institutes of Health’s Biomarkers Consortium (BC) embraces government, industry, patient advocacy groups, and not-for-profit organizations, each of which has a stake in the identification, the development, and the seeking of regulatory approval for biomarkers. The BC addresses one of the most pressing needs in the diagnosis and treatment of disease: the development and the seeking of regulatory approval for disease biomarkers and surrogates. The core operations of the Biomarkers Consortium are supported through the contributing membership     program. Organizations representing private industry (including the pharmaceutical, biotechnology, diagnostics, and information technology industries) and not-for-profit organizations (including associations, advocacy groups, trade organizations, and philanthropic organizations) that wish to support biomarkers development are eligible to become contributing members.


About the Foundation for the National Institutes of Health:

The Foundation for the National Institutes of Health (FNIH) creates and manages alliances with public and private Institutions in support of the mission of the NIH, the world’s premier medical research agency. The FNIH works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization.